NCT06017518

Brief Summary

multicenter retrospective and prospective study in patients with high-grade osteosarcoma

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
150

participants targeted

Target at P50-P75 for all trials

Timeline
1mo left

Started Jun 2022

Longer than P75 for all trials

Geographic Reach
1 country

2 active sites

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress97%
Jun 2022Jun 2026

Study Start

First participant enrolled

June 13, 2022

Completed
1.2 years until next milestone

First Submitted

Initial submission to the registry

August 24, 2023

Completed
6 days until next milestone

First Posted

Study publicly available on registry

August 30, 2023

Completed
2.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 30, 2026

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 30, 2026

Last Updated

September 22, 2025

Status Verified

September 1, 2025

Enrollment Period

4 years

First QC Date

August 24, 2023

Last Update Submit

September 19, 2025

Conditions

Osteosarcoma

Outcome Measures

Primary Outcomes (1)

  • post local relapse survival

    the aim of the study is to analyse the factors influencing post local relapse survival

    24 months follow up

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients who experienced local relapse as first event of recurrence after treatment for localized high-grade osteosarcoma of bone, including cases with synchronous lung metastases

You may qualify if:

  • Patients who experienced LR as first event of recurrence after treatment for localized high-grade osteosarcoma of bone, including cases with synchronous lung metastases
  • Adequate patient compliance to follow-up visits
  • Written informed consent prior to any study-specific analysis and/or data collection
  • No age limits

You may not qualify if:

  • Cases of LR demonstrated after \> 3 months after metastatic disease
  • Impossibility to ensure adequate compliance

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

IRCCS Istituto Ortopedico Rizzoli

Bologna, BO, 40136, Italy

RECRUITING

Azienda Ospedaliero-Universitaria Pisana

Pisa, PI, 56126, Italy

RECRUITING

MeSH Terms

Conditions

Osteosarcoma

Condition Hierarchy (Ancestors)

Neoplasms, Bone TissueNeoplasms, Connective TissueNeoplasms, Connective and Soft TissueNeoplasms by Histologic TypeNeoplasmsSarcoma

Central Study Contacts

Emanuela Palmerini, MD

CONTACT

051/6366emanuela.palmerini@ior.it

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 24, 2023

First Posted

August 30, 2023

Study Start

June 13, 2022

Primary Completion (Estimated)

June 30, 2026

Study Completion (Estimated)

June 30, 2026

Last Updated

September 22, 2025

Record last verified: 2025-09

Locations

IT(2)